Skip to content

Effect of Pentoxifylline in improvement Myocardial Injury in Patients with ST-elevation myocardial infarction treated by primary percutaneous coronary intervention

Effect of Pentoxifylline in improvement Myocardial Injury in Patients with ST-elevation myocardial infarction treated by primary percutaneous coronary intervention

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20240323061353N1
Enrollment
70
Registered
2024-06-24
Start date
2024-06-29
Completion date
Unknown
Last updated
2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial infarction. ST elevation (STEMI) myocardial infarction of unspecified site

Interventions

Intervention 1: Intervention group: Receive 1200 mg oral pentoxifylline (maximum daily dose of pentoxifylline
three 400 mg tablets, generic form) immediately before PCI treatment. Intervention 2: Control group: Standard treatment for STEMI is according to the American College of Heart Foundation (ACCF)/Americ

Sponsors

Bagheiat-allah University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Diagnosis of STEMI, as chest pain lasting more than 30 minutes and less than 12 hours with ST-segment elevation at the J point on the ECG for more than 1 mm in at least two consecutive leads Precancerous coronary intervention successful sinus rhythm Informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Recent history (within 3 months) of coronary artery bypass grafting Receive thrombolytic therapy Recent electrophysiological interventions of the heart Cardiogenic shock at the time of presentation History of kidney failure (Creatinine > 2.5 mg/dL) Allergy and contraindication to aspirin, clopidogrel or pentoxifylline Those who are pregnant or breastfeeding Dissatisfaction and those who want to stop the study at any time

Design outcomes

Primary

MeasureTime frame
Troponion I. Timepoint: Upon entering the emergency room and then 8, 16 and 32 hours after revascularization treatment. Method of measurement: Blood test.;Interleukin 6. Timepoint: On arrival in the emergency room and 48 hours and 15 days after revascularization treatment. Method of measurement: Blood Test.;Hs-CRP. Timepoint: On arrival in the emergency room and 48 hours and 15 days after revascularization treatment. Method of measurement: Blood test.;CPK. Timepoint: On arrival to the emergency department as a baseline sample and every 8 hours to 48 hours after revascularization treatment. Method of measurement: Blood test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAlireza Nasiri

Bagheiat-allah University of Medical Sciences

seyedjavad71@gmail.com+98 21 4445 6022

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026